# US 2026/0027205 A1 · Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0027205 A1
- Document ID: US20260027205A1
- Status: Published application
- Kind: A1
- Application number: 19/346,638
- Filed: 2025-10-01
- Published: 2026-01-29
- Earliest claimed: 2017-05-02
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme LLC
- Inventors: Manoj K. Sharma; Wendy Benjamin; Sarita Mittal; Ashwin Basarkar; Chakravarthy Nachu Narasimhan; Ramesh S. Kashi; Mohammed Shameem; Soumendu Bhattacharya; William P. Forrest, Jr.; Yogita Krishnamachari
- Web page: https://patentgrep.com/patent/US20260027205A1

## CPC

- A61K 39/39591: {Stabilisation, fragmentation}
- C07K 16/2818: {against CD28 or CD152}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.

## Claims

### Claim 1

An anti-human programmed death receptor 1 (PD-1) antibody formulation, comprising:
a) about 5 mg/mL to about 200 mg/mL of an anti-human PD-1 antibody;
b) about 5 mM to about 20 mM acetate or citrate buffer;
c) a stabilizer selected from the group consisting of:
i) about 6% to about 8% weight/volume (w/v) sucrose, trehalose or (2-hydroxypropyl)-β-cyclodextrin;
ii) about 3% to about 5% w/v mannitol, sorbitol, L-arginine, a pharmaceutically acceptable salt of L-arginine, L-proline, or a pharmaceutically acceptable salt of L-proline; and
iii) about 1.8% to about 2.2% w/v glycine, or a pharmaceutically acceptable salt thereof;
d) about 0.01% to about 0.10% non-ionic surfactant;
wherein the non-ionic surfactant is polysorbate 80, polysorbate 20, or poloxamer 188, and
wherein the anti-human PD-1 antibody is pembrolizumab.

### Claim 2 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the formulation has a pH between 5.0 and 6.0.

### Claim 3 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the buffer is acetate.

### Claim 4 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the buffer is citrate.

### Claim 5 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, further comprising about 1% to about 3% w/v L-arginine, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the stabilizer is about 6% to about 8% weight/volume (w/v) sucrose.

### Claim 7 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the stabilizer is about 6% to about 8% weight/volume (w/v) trehalose.

### Claim 8 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the stabilizer is about 6% to about 8% weight/volume (w/v) (2-hydroxypropyl)-β-cyclodextrin.

### Claim 9 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the stabilizer is about 3% to about 5% w/v mannitol.

### Claim 10 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the stabilizer is 3% to about 5% w/v sorbitol.

### Claim 11 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the stabilizer is 3% to about 5% w/v L-arginine or a pharmaceutically acceptable salt of L-arginine.

### Claim 12 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the stabilizer is 3% to about 5% w/v L-proline, or a pharmaceutically acceptable salt of L-proline.

### Claim 13 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the stabilizer is about 1.8% to about 2.2% w/v glycine, or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the non-ionic surfactant is polysorbate 80.

### Claim 15 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the non-ionic surfactant is polysorbate 20.

### Claim 16 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the non-ionic surfactant is poloxamer 188.

### Claim 17 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the formulation further comprises about 1 mM to about 20 mM anti-oxidant.

### Claim 18 (depends on 17)

The anti-human PD-1 antibody formulation of claim 17, wherein the anti-oxidant is L-methionine, or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The anti-human PD-1 antibody formulation of claim 18, wherein the L-methionine is L-methionine HCl.

### Claim 20 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the formulation is a liquid formulation.

### Claim 21 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the concentration of pembrolizumab is about 25 mg/mL to about 100 mg/mL.

### Claim 22 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the concentration of pembrolizumab is about 25 mg/mL.

### Claim 23 (depends on 1)

The anti-human PD-1 antibody formulation of claim 1, wherein the concentration of pembrolizumab is about 165 mg/mL to about 170 mg/mL.

### Claim 24

A method of treating cancer in a human patient in need thereof, the method comprising administering to the human patient an effective amount of an anti-human PD-1 antibody formulation comprising:
a) about 5 mg/mL to about 200 mg/mL of an anti-human PD-1 antibody;
b) about 5 mM to about 20 mM acetate or citrate buffer;
c) a stabilizer selected from the group consisting of:
i) about 6% to about 8% weight/volume (w/v) sucrose, trehalose or (2-hydroxypropyl)-β-cyclodextrin;
ii) about 3% to about 5% w/v mannitol, sorbitol, L-arginine, a pharmaceutically acceptable salt of L-arginine, L-proline, or a pharmaceutically acceptable salt of L-proline; and
iii) about 1.8% to about 2.2% w/v glycine, or a pharmaceutically acceptable salt thereof;
d) about 0.01% to about 0.10% non-ionic surfactant;
wherein the non-ionic surfactant is polysorbate 80, polysorbate 20, or poloxamer 188, and wherein the anti-human PD-1 antibody is pembrolizumab.

### Claim 25 (depends on 24)

The method of claim 24, wherein the concentration of pembrolizumab is about 25 mg/mL.

### Claim 26 (depends on 24)

The method of claim 24, wherein the concentration of pembrolizumab is about 165 mg/mL to about 170 mg/mL.

### Claim 27 (depends on 24)

The method of claim 24, wherein the formulation is administered by subcutaneous administration.

### Claim 28 (depends on 24)

The method of claim 24, wherein the cancer is selected from the group consisting of: melanoma, lung cancer, head and neck cancer, bladder cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular cancer, lymphoma, renal cancer, mesothelioma, ovarian cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, salivary cancer, prostate cancer (e.g. hormone refractory prostate adenocarcinoma), pancreatic cancer, colon cancer, esophageal cancer, liver cancer, thyroid cancer, glioblastoma, glioma, and other neoplastic malignancies.

### Claim 29 (depends on 24)

The anti-human PD-1 antibody formulation of claim 24, wherein the buffer is acetate.

### Claim 30 (depends on 24)

The anti-human PD-1 antibody formulation of claim 24, wherein the buffer is citrate.
